origins (Quattrochi and Tukey, 1993; Werlinder at al., 2000; Jeuken et al., 2003) .
Canonically, AhR is known to modulate the xenobiotic enzyme battery specifically cytochrome P4501A1 (Cyp1A1) but recent evidence supports AhR regulation of genes important to adaptive immunity including the inflammatory cytokine Interluekin 6 and immunoglobulin (Ig) (DiNatale et al., 2010 , DiNatale et al., 2011 , Sulentic and Kaminski, 2010 . Indeed, we have recently shown variety of dioxin and non dioxin AhR agonists inhibit Ig expression in the CH12.LX murine B cell line however the BCL-1 cell line which does not express the AhR is insensitive to treatment with TCDD and other dioxin congeners (Henseler et al., 2009; Sulentic et al., 1997) . Similarly, Vorderstrasse et al. (2001) sequestered in the cytosol by chaperone proteins p23, XAP2, and hsp90, upon ligand-binding the AhR-complex translocates to the nucleus where it sheds the chaperone proteins, heterodimerizing with the aryl hydrocarbon receptor nuclear translocator protein (AhRNT). The AhR-AhRNT complex binds dioxin responsive elements (DRE) in the regulatory regions of dioxin-sensitive genes interacting with the basal transcription apparatus and other transcription factors causing changes in transcription (e.g. increasing the transcription of Cyp1A1). Cytosol& Nucleus& Cyp1A1$ Clearly, the AhR plays an obligatory role during TCDD dependent inhibition of Ig expression in B cells however a mechanism has yet to be characterized and an Ig regulatory target for the AhR not identified. Responsible for humoral immunity, the Ig is a tetrameric protein comprised of two identical heavy (IgH) and light (IgL) chain peptides (Fig. 3) . The genes encoding IgH and IgL (Igh and Igl) require coordinated expression for effective assembly and expression. Interestingly TCDD not only inhibits Ig protein expression in CH12.LX cells but also transcription of Igh and Igl (Fernando et al., 2012; Henseler et al., 2009; Yoo et al., 2004; Sulentic et al., 2000) .
Of the Ig genes, regulation of Igh is the best understood and is achieved through a variable heavy chain promoter (V H ), an intronic enhancer (E µ ), and the 3'Igh regulatory region (3'IghRR) (Fig. 4) . Primarily activated in terminally differentiated plasma B cells, the 3'IghRR provides for high Igh expression in plasma B cells as well as class-switch recombination (CSR), a DNA recombination event during which the type of Ig expressed is changed from IgM to one (e.g. IgG, IgE, or IgA) that interacts with a separate array of effector molecules and cells Cogne et al., 1994 , Dunnick et al., 2005 . The murine 3'IghRR (mo-3'IghRR) contains four DNase I hypersensitivity sites (hs3A, hs1,2, hs4, and hs3B) that act as enhancers (Reviewed by Khamlichi et al., 2000) . Our lab has previously characterized two DREs capable of binding ligand-activated AhR in the hs1,2 and hs4 enhancers suggesting this region is sensitive to TCDD-AhR (Sulentic et al., 2000) . Indeed both transiently and stably expressed 3'IghRR reporter constructs are down regulated by TCDD in CH12.LX cells (Henseler et al., 2009) . Furthermore, studies reveal that 3'IghRR activity is inhibited with greater potency by ligand with higher affinity for the AhR protein (Henseler at al., 2009) . Figure 4 . Schematic of the mouse immunoglobulin heavy chain gene locus. V H , variable heavy chain promoter; Eµ, intronic enhancer (µ) enhancer; closed black rectangles, germline promoters upstream of their heavy chain constant region; 3ˊ IghRR, 3ˊ immunoglobulin heavy chain regulatory region containing the hs3a, hs1,2, hs3b, and hs4 enhancers.
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3'IghRR
Although previous studies suggest AhR regulates Ig expression through modulating the 3'IghRR, the data is correlative and a conclusive link has yet to be drawn. In the current study we utilized an IgA expressing CH12.LX variant that stably expresses the previously characterized 3'IghRR-regulated γ2b-transgene (Henseler et al., 2009 Any dysregulation of these processes has significant health ramifications. In addition the 3'IghRR has also been associated with several diseases including Burkitt's lymphoma, celiac disease, and IgA nephropathy (Wang et al., 2005; Frezza et al., 2004; Auptetit et al., 2000) . Therefore, modulation of the 3'IghRR by AhR via environmentally ubiquitous dioxin and nondioxin agonists has the potential to influence the severity and/or incidence of human disease.
II. MATERIALS AND METHODS
Chemicals and Reagents
AhR antagonist (CH-223191) was purchased from EMD4Biosciences at > 95% purity (Newark, NJ) and suspended in 100% dimethyl sulfoxide (DMSO). TCDD (99.1% purity) in 100% DMSO was purchased from Accustandard (New Haven, CT). DMSO and lipopolysaccharide (LPS, Escherichia coli) were purchased from Sigma-Aldrich (Atlanta, GA).
Cell Model
The CH12.γ2b-3'IghRR cell line, developed by our lab (Henseler et al., 2009) PCR and ELISA analysis verified that CH12.γ2b-3'IgH cells do not contain an endogenous form of the γ2b gene. The γ2b-transgene is sensitive to activation by LPS through TLR4 signaling with maximal transgene expression 48 hours post LPS treatment (Henseler et al., 2009 ). All cells were grown in a 37˚C
incubator with 5% CO 2 injection. Cells were maintained in RPMI 1640 (Mediatech, Herndon, VA) media supplemented with 10% bovine calf serum (Hyclone Laboratories, Logan, UT), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 13.5 mM HEPES, 100 units/mL penicillin, 50 µM 2-mercaptoethanol, and 100 µg/mL streptomycin (Hyclone Laboratories). 
Stable AhR Knockdown
CH12.γ2b-3'IgH cells (5 x 10 3 cells/mL) were suspended in media containing 16 µg/mL polybrene (American Bioanalytical, Natick, MA) and 0.1 mL (500 cells)
immediately seeded in 96-well culture plates with either shAhR11 or shAhR12-containing lentiviral particles. Culture plates were centrifuged for 30 minutes at 1100 x g before supernatants were discarded and replaced with 200 µL media.
After 24 hr the culture plates were centrifuged at 3000 rpm (5 min), the supernatants replaced with puromycin (Invivogen, San Diego, CA) selective media (1µg/mL). Puromycin selective media was replaced every 72 hr for approximately 4 weeks until cell density and culture volumes were sufficient to harvest whole cell lysate from 10 mL of cells and 1.0 x 10 6 cell stocks were frozen in liquid nitrogen for future use. 
Chemical Treatment
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of IgA and γ2b in cell lysates were analyzed as described previously (Henseler, et al. 2009 ). Colorimetric detection was performed every minute for 1 hour using a Spectramax Plus 284 automated microplate reader with a 405-nm filter (Molecular Devices, Sunnyvale, CA). Sample concentrations of
IgA and γ2b were calculated by the SOFTmax PRO analysis software (Molecular Devices) using a standard curve generated from the kinetic rate of absorption for known IgA or γ2b concentrations.
RNA Isolation
After the incubation period, cells were centrifuged at 3000 rpm, collected in 0.25 mL of TRI Reagent (Sigma-Aldrich, St. Louis, MO), and stored at -80˚C.
Samples were thawed at room temperature and centrifuged at 12,000 x g for 10 minutes. The supernatant was collected into Phase Lock Gel Tubes (5 PRIME, Gaithersburg, MD), mixed with 0.1 volume of 1-bromo-3-chloropropane followed by a 10 minute room temperature incubation and the addition of 0.1 volume of nuclease-free water. Samples were then centrifuged at 12,000 x g for 5 minutes.
The aqueous phase was retained and mixed with 0.125 mL isopropanol then centrifuged at 12,000 x g for 8 minutes to precipitate RNA. The RNA pellet was washed with 0.25 mL 70% ethanol, air dried, and suspended in nuclease-free water. Samples were stored at -20˚C until analysis. 
Statistical Analysis
The mean±SE (n=4) was calculated for all treatment groups of each ELISA experiment. IgA and γ2b expression are shown as a percent of the DMSO control. The DMSO control mean was set to 100% and the data was Wild Type cells were determined by a one-tailed t test.
III. RESULTS
Stable knockdown of the AhR and the AhR antagonist CH223191 disrupt canonical AhR signaling in the CH12.LX B cell line
To determine if the AhR mediates TCDD-induced inhibition of Ig expression by disrupting 3'IghRR transcriptional activity, we utilized an IgA-expressing CH12.LX cell line variant that stably expresses a γ2b transgene regulated by the 3'IghRR (CH12.γ2b-3'IghRR cells) (Henseler et al., 2009 ). CH12.γ2b-3'IghRR cells were stably transduced with lentiviral particles containing shRNA targeted to the AhR.
Highly variable levels of AhR-knock down were observed by western blot during the course of screening >100 cell populations from CH12.γ2b-3'IghRR cells transduced with lentiviral particles containing five separate shRNA sequences targeted to AhR (data not shown). Two independent shRNA sequences (denoted shAhR11 and shAhR12) stably knocked down AhR by at least 50% (Fig.1) . In order to ensure results seen in the shAhR cell populations were not the result of shRNA off target effects, we also utilized the previously characterized competitive AhR antagonist, CH-223191, to disrupt AhR signaling in the CH12.γ2b-3'IghRR cells (Kim et al., 2006; Zhoa et al., 2010) . Cytochrome (Fig. 6 ).
Figure 6. Effect of reduced AhR expression and a competitive AhR antagonist (CH-223191) on TCDD-induced CYP1A1 expression. "Wild Type" (WT) refers to CH12.LX murine B-cells that endogenously express
IgA and stably express a 3'IghRR-regulated γ2b transgene (CH12.γ2b-3'IghRR cells). "shAhR" denotes CH12.γ2b-3'IghRR cells that stably express shRNA to AhR (shAhR). Stable expression of shAhR was achieved using lentiviral-mediated delivery of shAhR constructs (denoted shAhR11 and shAhR12). (A); Whole cell lysates were collected from WT and shAhR cells. 20 µg of protein was subjected to western blot analysis of AhR and β-actin proteins. (B); WT, shAhR11, and shAhR12 cells (5.0 x 10 5 cells/mL) were culture in the presence of 10 nM TCDD, 0.11% DMSO vehicle, or left in the absence of treatment (NA) for 8 hours. WT cells were also subjected to 30 µM AhR Antagonist (CH-223191) treatment (AhRA) for 1 hour prior to TCDD. Total RNA was extracted, one microgram was reverse transcribed to cDNA, and 5 ng of cDNA was used to amplify Cyp1A1 and β-actin via SYBR Green real-time PCR. NA and DMSO treatment caused no appreciable expression of Cyp1A1 as it is only expressed when activated my ligand (i.e. TCDD), therefore results are expressed as relative quantification (RQ) values compared to TCDD-treated WT cells. The data is representative of at least two separate experiments (n=3 for each treatment group). Statistical differences compared to respective WT TCDD treatment group were determined by a one-tailed t test.
Disrupting AhR signaling reverses TCDD-induced inhibition of 3'IghRR activation and Ig expression in LPS-activated B cells
AhR has long been suspected to mediate TCDD-induced inhibition of Ig expression, as supported by structure-activity relationships revealing that ligands with increasing affinity for the AhR inhibit the Ig expression with greater sensitivity (Sulentic et al., 2000) . In addition, AhR null mice and an AhR-deficient murine B cell line (BCL-1) are refractory to TCDD treatment further highlighting the importance of the AhR in mediating the inhibitory effect of TCDD on Ig expression (Vorderstrasse et al., 2001; Sulentic et al., 1998) . However despite extensive study, there remains a paucity of mechanistic data to explain how the AhR regulates Ig expression. Our lab has previously shown that a key regulator of Igh transcription and therefore Ig production, the 3'IghRR, not only contains putative DRE sites but is also sensitive to a variety of AhR agonists (Fernando et al., 2012; Henseler et al., 2009) . Despite a putative link, the role of the AhR in directly mediating these effects was not established.
At this time no cis-acting transcriptional target has been identified that links ligand-activation of the AhR to inhibition of Ig expression. Due to its sensitivity to AhR-ligands, the presence of DREs, and its paramount importance to Ig expression and CSTR, the 3'IghRR is a likely transcriptional target of the AhR. As such we sought to elucidate the correlative link between the AhR and the 3'IghRR using a competitive AhR antagonist (CH-223191) or shRNA targeted to AhR in CH12.γ2b-3'IghRR cells (denoted shAhR11 and shAhR12) allowing for simultaneous surveillance of AhR-dependent changes in 3'IghRR transcriptional activity and Ig expression. Consistent with our previous studies, TCDD inhibited LPS-activation of both the γ2b transgene and endogenous IgA proteins ( Fig. 7 and 8). Following a one hour pretreatment with CH-223191 (30 µM), TCDDinduced inhibition of both the γ2b transgene and endogenous IgA protein was completely mitigated (Fig. 7) . In addition both shAhR11 and shAhR12 cell models were refractory to TCDD-treatment compared to the wild type (CH12.γ2b-3'IghRR) parental cells (Fig. 8) . Our data support a direct effect on the 3'IghRR (CH-223191) . CH12.γ2b-3'IghRR cells were pretreated for 1 h with CH-223191 (30 µM) or vehicle (0.1% DMSO) followed by treatment for 48 h with TCDD (10 nM) or vehicle (0.01% DMSO) in the presence of LPS stimulation (1 µg/mL). (A); γ2b and IgA expression (mean±S.E., n=4) normalized to 2 µg total protein was determined by ELISA. (B); γ2b and IgA expression transformed to percent effect with the DMSO control set to 100%. NA denotes the naïve control. Significance was determined by a 1-way ANOVA followed by a Dunnet post hoc test. "**" and "*" denote significance from the DMSO control at p<0.01 and p<0.05 respectively. " ‡ ‡ ‡" and " ‡ ‡" denote significance of the NA control from the LPS control at p<0.001 and p<0.01 respectively. shAhR11 and shAhR12) . Wild Type and shAhR cells were treated with vehicle (0.1% DMSO) and TCDD (10 nM) in the presence of LPS (1 µg/mL) stimulation for 48 hours. Data represents γ2b (A) and IgA (B) expression as determined by ELISA in 2 µg total protein and transformed to percent effect (mean±S.E., n=4) with the DMSO control set to 100%. NA denotes the naïve control. Significance was determined by a 1-way ANOVA followed by a Dunnet post hoc test. "**" and "*" denote significance from the DMSO control at p<0.01 and p<0.05 respectively. " ‡ ‡ ‡" and " ‡ ‡" denote significance of the NA control from the LPS control at p<0.001 and p<0.01 respectively.
IV. DISCUSSION
Compromised immune function, specifically suppressed Ig expression, is one of the most sensitive toxicological consequences in TCDD-treated laboratory animals (Reviewed by Sulentic and Kaminski, 2012) . Although established to be AhR-dependent, a mechanism has remained elusive and is a significant human health question given the plethora of nondioxin compounds of pharmaceutical and dietary origin shown to modulate the AhR (Reviewed by Stejskalova et al., 2011) . Indeed, a recent study by Lu et al. (2010) The mouse 3'IghRR (mo-3'IghRR) is a large ~40 kb region and contains at least four enhancer domains (i.e. hs3A, hs1,2; hs3B; hs4) with binding sites for many transcription factors including a DRE capable of binding the AhR within both the hs1,2 and hs4 enhancers (Reviewed by Pinaud et al., 2011; Sulentic et al., 2000) . A single enhancer or a combination of these enhancers or specific transcription factor binding sites within the enhancers along with the AhR may direct the overall inhibition of the mo-3'IghRR. Relevant to this notion is the strikingly different transcriptional behavior exhibited by the hs1,2 and hs4 enhancers when in isolation in luciferase reporter constructs. While transcriptional activity of the hs1,2 enhancer is inhibited by TCDD, the hs4 enhancer is syngeristically activated by TCDD and LPS treatment in CH12.LX B cells (Fernando et al., 2012; Sulentic et al., 2004) .
Undoubtedly luciferase reporter constructs evaluating individual enhancers may not mimic enhancer behavior in the context of the entire mo-3'IghRR and chromatin. We previously reported that expression of a stablyexpressed γ2b reporter construct under transcriptional control of either the entire mo-3'IghRR or the hs1,2/hs3A enhancer pair is inhibited by TCDD (Henseler et al., 2009; Fernando et al., 2012) . In our current study we show that an AhR antagonist ameliorates TCDD-dependent inhibition of not only the mo-3'IghRR but also the hs1,2/hs3A enhancer pair further suggesting that the DREcontaining, hs1,2 is the primary target of TCDD-AhR. Indeed, TCDD was recently shown to modulate the human hs1,2 (hu-hs1,2) enhancer in a concentration-dependent manner (Fernando et al., 2012) . Interestingly the hu-hs1,2 is highly polymorphic, characterized by an ~38 bp invariant sequence (IS) that contains a DRE-like site and may be repeated in tandem up to three times (Denizot et al., 2001; Fernando et al., 2012) . Studies using the AhR Antagonist CH-223191 revealed that hu-hs1,2 enhancers containing one, two, or three copies of the IS are activated by TCDD in an AhRdependent manner, albeit to varying extents depending upon the number of IS (Fernando et al., 2012) . However, the aforementioned study was performed using a transiently expressed reporter-plasmid system and may not be reflective Deficient Ig expression in response to TCDD has been well established for over thirty years in mouse models however the literature contains a paucity of mechanistic data (Reviewed by Sulentic and Kaminski, 2010) . To the best of our knowledge no study has identified a cis-acting transcriptional target for the AhR that explains AhR-dependent inhibition of Ig expression; therefore our study fills a critical mechanistic data gap. Recent evidence suggests that a proportion of the human population is also be sensitive to the inhibitory effect of TCDD, a finding that may be due in part to AhR-dependent modulation of the hu-hs1,2 enhancer within the human 3'IghRR (Lu et al., 2010; Fernando et al., 2012) . Interestingly IS within the hu-hs1,2 have been correlated with the incidence of many immunerelated diseases including celiac disease, IgA nephropathy, systemic sclerosis, plaque psoriasis, psoriatic arthritis, dermatitis herpetiformis, and rheumatoid arthritis (Frezza et al., 2004; Aupetit et al., 2000; Frezza et al., 2007; Cianci et al., 2008; Tolusso et al., 2009) . Cianci, R., Giambra, V., Mattioli, C., Esposito, M., Cammarota, G., Scibilia, G., .
. . Frezza, D. (2008) . Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis. J Invest Dermatol, 128(8), 1920 Dermatol, 128(8), -1924 Dermatol, 128(8), . doi: 10.1038 Dermatol, 128(8), /jid.2008 
